Pharmafile Logo
Pharmafocus logo
Advanced Search

NHE3

Showing 1 posts of 1 posts found.

Astrazeneca image

AZ licences renal disease compound

October 9, 2012
Research and Development, Sales and Marketing Ardelyx, AstraZeneca, NHE3

AstraZeneca has signed an agreement giving it worldwide exclusive rights to California-based Ardelyx’s NHE3 inhibitor programme targeting liver and kidney …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025